CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.2559
-0.0041 (-1.58%)
Oct 6, 2025, 3:58 PM EDT
CytoDyn Employees
CytoDyn had 13 employees as of May 31, 2025. The number of employees increased by 4 or 44.44% compared to the previous year.
Employees
13
Change (1Y)
4
Growth (1Y)
44.44%
Revenue / Employee
n/a
Profits / Employee
$174,000
Market Cap
321.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 13 | 4 | 44.44% |
| May 31, 2024 | 9 | -3 | -25.00% |
| May 31, 2023 | 12 | -11 | -47.83% |
| May 31, 2022 | 23 | -1 | -4.17% |
| May 31, 2021 | 24 | 5 | 26.32% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Jushi Holdings | 1,234 |
| Nuo Therapeutics | 9 |
CytoDyn News
- 6 days ago - September 2025 Letter to Shareholders - GlobeNewsWire
- 11 days ago - CytoDyn (CYDY) Highlights Promising Cancer Research at AACR Conference - GuruFocus
- 11 days ago - CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity - GlobeNewsWire
- 20 days ago - CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity - GlobeNewsWire
- 4 weeks ago - CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 weeks ago - CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - CytoDyn files $100M mixed securities shelf - Seeking Alpha
- 3 months ago - CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab - GlobeNewsWire